当分子生物学改变临床瘤学时:EGFR在结直肠癌中的旅程
Pietro Paolo Vitiello1,2, Nadia Saoudi González2,3, Alberto Bardelli1,2
1Department of Oncology, University of Torino, Italy.
精确瘤学是癌症治疗的基础,由于耐药性,在结直肠癌 (CRC) 中面临着表皮生长因子受体 (EGFR) 向治疗的挑战. 在了解EGFR信号和液体活检方面的进展通过解决耐药性机制来完善治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 增长因子的发现是精确瘤学的基础.
- 在结直肠癌 (CRC) 中准表皮生长因子受体 (EGFR) 最初显示出希望,但面临着重大抵抗挑战.
- 耐药性机制限制了抗EGFR药物的治疗疗效.
研究的目的:
- 探索抗EGFR治疗策略在结直肠癌中的演变.
- 突出了解EGFR信号通路生物学在克服治疗耐药性的作用.
- 为了证明液体活检的进步如何促进癌症演变和治疗改进的实时监测.
主要方法:
- 针对EGFR的药物的临床前和临床开发.
- 研究内在和获得的抵抗机制.
- 液体活检方法的应用,用于实时追踪癌症进化.
- 生物见解与临床发展的相关性.
主要成果:
- 在CRC中抗EGFR药物的初始临床开发受到耐药性的阻碍.
- 对EGFR通路生物学和液体活检技术的更好理解,使得抗EGFR治疗的改进成为可能.
- 识别抵抗机制直接告知了克服它们的策略的发展.
结论:
- 生物知识和临床发展的共同进化对于完善向疗法至关重要.
- 液体活检和更深入地了解癌症生物学可以克服抗EGFR药物等治疗方法的耐药性.
- 这种将生物见解与临床策略相结合的范式可以加速超越向治疗的治疗进步.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
